CURRENT Med Diag & Treatment

by Skyscape Medpresso Inc


Medical

free



"Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is r...

Read more

"Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is required to unlock all content. The most popular, relied-upon guide to internal medicine for 60 years! Single source reference that has authoritative, evidence-based coverage of more than 1,000 diseases and disorders including concise, yet thorough synopsis of diagnosis and treatment. Written by clinicians renowned in their respective fields, this trusted classic offers expert advice on all aspects of outpatient and inpatient medical care.The #1 annually updated general medical text—presents the most important diagnostic and treatment recommendations as well as the most useful new clinical developments in every field of adult medicine.CURRENT Medical Diagnosis & Treatment 2024 reflects the latest developments in medicine, guidelines, references, and more. Helps students, residents, and clinicians to build their medical knowledge, expertise, and confidence.CURRENT Medical Diagnosis & Treatment 2024 features:- A comprehensive approach to patient care, focusing on the diagnostic tools relevant to daily practice- Coverage of more than 1,000 diseases and disorders- Hundreds of drug treatment tables for quick access to indexed trade names- Annual updates to topics in all chapters in a consistent format, drugs, tables, and images- Year in Review highlighting the many topics with significant clinical changes over the last year- Essentials of Diagnosis for most diseases/disorders- Diagnostic and treatment algorithms present complex information in an at-a-glance style- Hundreds of full-color photos and illustrationsNew to this edition:- Latest USPSFT recommendations for cardiovascular risk prevention- Significant new opioid prescribing guidelines from the CDC- Clarification on the distinction between uncontrolled hypertensive and hypertension emergency- Latest classification of lymphomas released by the WHO- Recommendations for the initiation and titration of treatment for chronic hypertension in pregnancy- Current treatment guidelines and medications for H pylori infection- Classification of the role, dosing, and potential risks of JAK inhibitors and anti-23 antibody (Risankizumab) in the treatment of IBD- Updates that underscore the growing utility of combination treatments for high LDL levels, especially among high and very high-risk patients- The WHO revision of the pathological classification of renal cell carcinoma to assist with prognosis prediction and treatment decisions No internet connection is required to access the content after the initial download. Find information quickly using powerful SmartSearch technology. Search part of term for those hard to spell medical terms. Content licensed from printed ISBN 10: 1265556032 ISBN 13: 9781265556037 SUBSCRIPTION :Please choose an auto renewable subscription plan to receive content access & continuous updates. Your subscription automatically renews as per your plan, so you always have the latest content. Yearly auto-renewing payments-$64.99 Payment will be charged to your mode of payment you select at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your App “Settings” and tapping “Manage Subscriptions”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable. If you have any questions or comments, email us any time: [email protected] or call 508-299-30000 Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspxTerms and Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx Editor(s): Maxine A. Papadakis, Stephen J. McPhee, Michael W. Rabow, Kenneth R. McQuaid, Monica GandhiPublisher: The McGraw-Hill Companies, Inc.